Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison.
about
Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infectionDevelopment of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxisHenipavirus neutralising antibodies in an isolated island population of African fruit batsLyssavirus-reactive antibodies in Swedish batsComparative serological assays for the study of h5 and h7 avian influenza viruses.The production and development of H7 Influenza virus pseudotypes for the study of humoral responses against avian virusesLlama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120Rabies-specific antibodies: measuring surrogates of protection against a fatal disease.More accurate insight into the incidence of human rabies in developing countries through validated laboratory techniquesMultiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studiesPotent and broad neutralization of HIV-1 by a llama antibody elicited by immunization.Single domain antibody multimers confer protection against rabies infection.The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum.Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans.A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in AfricaDevelopment of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system.Production of influenza pseudotyped lentiviral particles and their use in influenza research and diagnosis: an update.Deciphering serology to understand the ecology of infectious diseases in wildlife.Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.The use of equine influenza pseudotypes for serological screeningThe Measles Virus Receptor SLAMF1 Can Mediate Particle Endocytosis.A recombinant rabies virus (ERAGS) for use in a bait vaccine for swine.Bat and pig IFN-induced transmembrane protein 3 restrict cell entry by influenza virus and lyssaviruses.Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1.Field-deployable, quantitative, rapid identification of active Ebola virus infection in unprocessed blood.Current status on the development of pseudoviruses for enveloped viruses.Laboratory diagnosis of human rabies: recent advances.Utilisation of Chimeric Lyssaviruses to Assess Vaccine Protection against Highly Divergent Lyssaviruses.Current progress with serological assays for exotic emerging/re-emerging virusesRetroviral Pseudotypes - From Scientific Tools to Clinical Utility
P2860
Q21245045-FDF95746-B2D0-440E-8657-82AC184A9CEFQ28601417-39CB8806-DE89-46ED-BC34-82667E963AA4Q28732845-18B774AE-CBF3-4F73-B4DA-FC45503A6CB2Q28817431-3E610270-8C27-4CDD-911E-E1965F75CEDAQ30354952-E414B3E9-47DF-4BDC-881F-2B3957A1B9A6Q30429267-2C0D09DA-357E-4B91-B4F2-DEF0D0B7ED86Q33374701-17E10896-674D-4141-AB8A-9A1E9F8FFF70Q33541002-3F55A42C-9857-4CA8-964D-7F33F2EE9F80Q33769901-666928C9-353C-45D1-A9FC-66BC0381D0A5Q33914496-A9CAFFE3-9D59-4FD3-A527-7BF1CBFE6A0AQ34284855-2CCFDEBB-567F-4ABC-ACC0-D926BDA54E55Q34971008-B7D3DB2C-34C8-4BFF-9212-683BF69DD45BQ35042225-7AF7853E-6D61-43CC-856D-49F17BE6EE12Q35105844-D8D5212F-6A36-4E9D-8FD5-106CD027EC0CQ35530244-BAD1F3CA-68ED-40AC-A65A-2670B3D40CEFQ35605579-37F49C7B-5B4E-47C8-85E0-5726A4E5DCFDQ36788708-ACA3961C-5262-4F6F-806B-CCE17A1456B3Q37461555-B93DF7C0-DF0F-43F3-9BCA-E3FD98B0EC2EQ37652192-3E8F448B-B9DC-4922-9BBF-04BF921823C6Q37866816-B29EC800-2097-4242-96A6-7528C3DFD973Q38126825-7649F0B7-6180-4639-B26C-837B4790F04FQ39621109-EFC67D7B-5BC5-4441-958D-C4AA6195DAECQ39670834-46EE3B84-3093-4B09-BF1A-11EAA8ABEC45Q40366503-5CF7C3D9-30C1-4BDE-8509-E81903AA350EQ40636735-A0A1D736-FEBB-4843-84B9-64A82731D513Q41525616-894422E1-9957-4F1A-93EC-E63CE303D034Q42546416-573D67A3-A4E5-4E4B-AFF6-50402856AB4AQ44106386-240B3B46-8831-44DC-9741-1254DAD51768Q47568014-1BBC0968-F712-4490-BC2F-3039BEEADCB6Q51328184-7A276D86-9BF2-4BF0-BFC6-364FBF35BDA5Q54255407-543904E5-CE19-4D63-9900-C52EB969C663Q57275156-03FAFBED-EEC0-404B-9A20-0426EE1C2588Q58382398-ABF6C169-13F1-4F2A-8526-E89457B35238
P2860
Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Investigating antibody neutral ...... s: a cross-species comparison.
@en
Investigating antibody neutral ...... s: a cross-species comparison.
@nl
type
label
Investigating antibody neutral ...... s: a cross-species comparison.
@en
Investigating antibody neutral ...... s: a cross-species comparison.
@nl
prefLabel
Investigating antibody neutral ...... s: a cross-species comparison.
@en
Investigating antibody neutral ...... s: a cross-species comparison.
@nl
P2860
P50
P356
P1476
Investigating antibody neutral ...... s: a cross-species comparison.
@en
P2093
Anthony R Fooks
Robin A Weiss
P2860
P304
P356
10.1099/VIR.0.2008/000349-0
P407
P577
2008-09-01T00:00:00Z